Combined treatment with auranofin and trametinib induces synergistic apoptosis in breast cancer cells

References

• Acharya, A., I. Das, D. Chandhok, and T. Saha. 2010. Redox regulation in cancer: A double-edged sword with therapeutic potential. Oxid. Med. Cell. Longev. 3 (1):23–34. doi:10.4161/oxim.3.1.10095.
   PubMed Web of Science ®Google Scholar
• Adjei, A. A., R. B. Cohen, W. Franklin, C. Morris, D. Wilson, J. R. Molina, L. J. Hanson, L. Gore, L. Chow, S. Leong, et al. 2008. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26 (13):2139–46. doi:10.1200/JCO.2007.14.4956.
   PubMed Web of Science ®Google Scholar
• Ahmad, D. A., O. H. Negm, M. L. Alabdullah, S. Mirza, M. R. Hamed, V. Band, A. R. Green, I. O. Ellis, and E. A. Rakha. 2016. Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Res. Treat. 159 (3):457–67. doi:10.1007/s10549-016-3967-9.
   PubMed Web of Science ®Google Scholar
• Atanaskova, N., V. G. Keshamouni, J. S. Krueger, J. A. Schwartz, F. Miller, and K. B. Reddy. 2002. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21:4000–4008.
   PubMed Web of Science ®Google Scholar
• Bhatia, M., K. L. McGrath, G. Di Trapani, P. Charoentong, F. Shah, M. M. King, F. M. Clarke, and K. F. Tonissen. 2016. The thioredoxin system in breast cancer cell invasion and migration. Redox Biol. 8:68–78. doi:10.1016/j.redox.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Cho, E., Y. J. Kwon, D. J. Ye, H. S. Baek, T. U. Kwon, H. K. Choi, and Y. J. Chun. 2019. G0/G1 switch 2 induces cell survival and metastasis through integrin-mediated signal transduction in human invasive breast cancer cells. Biomol. Ther. (Seoul) 27 (6):591–602. doi:10.4062/biomolther.2019.063.
   Web of Science ®Google Scholar
• Choi, N., and J. H. Sung. 2019. Udenafil induces the hair growth effect of adipose-derived stem cells. Biomol. Ther. (Seoul) 27 (4):404–13. doi:10.4062/biomolther.2018.195.
   PubMed Web of Science ®Google Scholar
• Chou, T.-C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (3):621–81. doi:10.1124/pr.58.3.10.
   PubMed Web of Science ®Google Scholar
• Coutts, A. S., and L. C. Murphy. 1998. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res. 58:4071–74.
   PubMed Web of Science ®Google Scholar
• Deschesnes, R. G., J. Huot, K. Valerie, and J. Landry. 2001. Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol. Biol. Cell. 12 (6):1569–82. doi:10.1091/mbc.12.6.1569.
   PubMed Web of Science ®Google Scholar
• Fan, C., W. Zheng, X. Fu, X. Li, Y. S. Wong, and T. Chen. 2014. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis. 5 (4):e1191. doi:10.1038/cddis.2014.132.
   PubMedGoogle Scholar
• Fiskus, W., N. Saba, M. Shen, M. Ghias, J. Liu, S. D. Gupta, L. Chauhan, R. Rao, S. Gunewardena, K. Schorno, et al. 2014. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 74 (6):2520–32. doi:10.1158/0008-5472.CAN-13-2033.
   PubMedGoogle Scholar
• Ghate, N. B., D. Chaudhuri, R. Sarkar, A. L. Sajem, S. Panja, J. Rout, N. Mandal, and A. B. Pant. 2013. An antioxidant extract of tropical Lichen, parmotrema reticulatum, induces cell cycle arrest and apoptosis in breast carcinoma cell line MCF-7. PLoS One 8 (12):e82293. doi:10.1371/journal.pone.0082293.
   PubMed Web of Science ®Google Scholar
• Gu, Y., M. Helenius, K. Vaananen, D. Bulanova, J. Saarela, A. Sokolenko, J. Martens, E. Imyanitov, and S. Kuznetsov. 2016. BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. Sci. Rep. 6 (1):28217. doi:10.1038/srep28217.
   PubMedGoogle Scholar
• Han, Y., P. Chen, Y. Zhang, W. Lu, W. Ding, Y. Luo, S. Wen, R. Xu, P. Liu, and P. Huang. 2019. Synergy between auranofin and celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism. Cancers (Basel) 11 (7):931. doi:10.3390/cancers11070931.
   Web of Science ®Google Scholar
• Hecht, F., C. F. Pessoa, L. B. Gentile, D. Rosenthal, D. P. Carvalho, and R. S. Fortunato. 2016. The role of oxidative stress on breast cancer development and therapy. Tumour Biol. 37 (4):4281–91. doi:10.1007/s13277-016-4873-9.
   PubMedGoogle Scholar
• Ittiudomrak, T., S. Puthong, S. Roytrakul, and C. Chanchao. 2019. α-Mangostin and apigenin induced cell cycle arrest and programmed cell death in SKOV-3 ovarian cancer cells. Toxicol. Res. 35 (2):167–79. doi:10.5487/TR.2019.35.2.167.
   PubMed Web of Science ®Google Scholar
• Jeong, J. J., N. Park, Y. J. Kwon, D. J. Ye, A. Moon, and Y. J. Chun. 2014. Role of annexin A5 in cisplatin-induced toxicity in renal cells: Molecular mechanism of apoptosis. J. Biol. Chem. 289 (4):2469–81. doi:10.1074/jbc.M113.450163.
   PubMed Web of Science ®Google Scholar
• Kwon, C. H., J. Y. Park, T. H. Kim, J. S. Woo, and Y. K. Kim. 2009. Ciglitazone induces apoptosis via activation of p38 MAPK and AIF nuclear translocation mediated by reactive oxygen species and Ca2+ in opossum kidney cells. Toxicology 257 (1–2):1–9. doi:10.1016/j.tox.2008.11.019.
   PubMed Web of Science ®Google Scholar
• Lee, G. H., S. W. Jin, S. J. Kim, T. H. Pham, J. H. Choi, and H. G. Jeong. 2019. Tetrabromobisphenol A induces MMP-9 expression via NADPH oxidase and the activation of ROS, MAPK, and Akt pathways in human breast cancer MCF-7 cells. Toxicol. Res. 35 (1):93–101. doi:10.5487/TR.2019.35.1.093.
   PubMed Web of Science ®Google Scholar
• Lee, J. E., Y. J. Kwon, H. S. Baek, D. J. Ye, E. Cho, H. K. Choi, K. S. Oh, and Y. J. Chun. 2017. Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells. Arch. Pharm. Res. 40 (6):746–59. doi:10.1007/s12272-017-0923-0.
   PubMed Web of Science ®Google Scholar
• Leung, E. Y., J. E. Kim, M. Askarian-Amiri, G. W. Rewcastle, G. J. Finlay, B. C. Baguley, and Y.-S. Ho. 2014. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: Examination of trametinib responses in cultured breast cancer lines. PLoS One 9 (8):e105792. doi:10.1371/journal.pone.0105792.
   PubMed Web of Science ®Google Scholar
• Lim, J. C., Z. You, G. Kim, and R. L. Levine. 2011. Methionine sulfoxide reductase A is a stereospecific methionine oxidase. Proc. Natl. Acad. Sci. U. S. A. 108 (26):10472–77. doi:10.1073/pnas.1101275108.
   PubMed Web of Science ®Google Scholar
• Liu, C., Z. Liu, M. Li, X. Li, Y. S. Wong, S. M. Ngai, W. Zheng, Y. Zhang, and T. Chen. 2013. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. PLoS One 8 (1):e53945. doi:10.1371/journal.pone.0053945.
   PubMed Web of Science ®Google Scholar
• Lugowska, I., H. Kosela-Paterczyk, K. Kozak, and P. Rutkowski. 2015. Trametinib: A MEK inhibitor for management of metastatic melanoma. Onco. Targets Ther. 8:2251–59.
   PubMed Web of Science ®Google Scholar
• Maillet, A., and S. Pervaiz. 2012. Redox regulation of p53, redox effectors regulated by p53: A subtle balance. Antioxid. Redox Signal. 16 (11):1285–94. doi:10.1089/ars.2011.4434.
   PubMed Web of Science ®Google Scholar
• Mirzoeva, O. K., D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, et al. 2009. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69 (2):565–72. doi:10.1158/0008-5472.CAN-08-3389.
   PubMed Web of Science ®Google Scholar
• Monteiro, H. P., F. T. Ogata, and A. Stern. 2017. Thioredoxin promotes survival signaling events under nitrosative/oxidative stress associated with cancer development. Biomed. J. 40 (4):189–99. doi:10.1016/j.bj.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Nobeyama, Y., Y. Watanabe, and H. Nakagawa. 2017. Silencing of G0/G1 switch gene 2 in cutaneous squamous cell carcinoma. PLoS One 12 (10):e0187047. doi:10.1371/journal.pone.0187047.
   PubMed Web of Science ®Google Scholar
• Omenn, G. S., G. E. Goodman, M. D. Thornquist, J. Balmes, M. R. Cullen, A. Glass, J. P. Keogh, F. L. Meyskens Jr., B. Valanis, J. H. Williams Jr., et al. 1996. Risk factors for lung cancer and for intervention effects in CARET, the Beta-carotene and retinol efficacy trial. J. Natl. Cancer Inst. 88 (21):1550–59. doi:10.1093/jnci/88.21.1550.
   PubMedGoogle Scholar
• Park, N., and Y.-J. Chun. 2014. Auranofin promotes mitochondrial apptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J. Toxicol. Environ. Health 77 (22–24):1467–76. doi:10.1080/15287394.2014.955834.
   PubMed Web of Science ®Google Scholar
• Qiu, J.-G., Y.-J. Zhang, Y. Li, J.-M. Zhao, W.-J. Zhang, Q.-W. Jiang, X.-L. Mei, Y.-Q. Xue, W.-M. Qin, Y. Yang, et al. 2015. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget 6 (17):15494–509. doi:10.18632/oncotarget.3820.
   PubMedGoogle Scholar
• Raj, L., T. Ide, A. U. Gurkar, M. Foley, M. Schenone, X. Li, N. J. Tolliday, T. R. Golub, S. A. Carr, A. F. Shamji, et al. 2011. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475 (7355):231–34. doi:10.1038/nature10167.
   PubMed Web of Science ®Google Scholar
• Rao, A. K., Y. S. Ziegler, I. X. McLeod, J. R. Yates, and A. M. Nardulli. 2009. Thioredoxin and thioredoxin reductase influence estrogen receptor α-mediated gene expression in human breast cancer cells. J. Mol. Endocrinol. 43 (6):251–61. doi:10.1677/JME-09-0053.
   PubMed Web of Science ®Google Scholar
• Riccardi, C., and I. Nicoletti. 2006. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1 (3):1458–61. doi:10.1038/nprot.2006.238.
   PubMed Web of Science ®Google Scholar
• Rigobello, M. P., V. Gandin, A. Folda, A. K. Rundlof, A. P. Fernandes, A. Bindoli, C. Marzano, and M. Bjornstedt. 2009. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radic. Biol, Med. 47 (6):710–21. doi:10.1016/j.freeradbiomed.2009.05.027.
   PubMed Web of Science ®Google Scholar
• Rinehart, J., A. A. Adjei, P. M. Lorusso, D. Waterhouse, J. R. Hecht, R. B. Natale, O. Hamid, M. Varterasian, P. Asbury, E. P. Kaldjian, et al. 2004. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22 (22):4456–62. doi:10.1200/JCO.2004.01.185.
   PubMed Web of Science ®Google Scholar
• Roder, C., and M. J. Thomson. 2015. Auranofin: Repurposing an old drug for a golden new age. Drugs R. D. 15 (1):13–20. doi:10.1007/s40268-015-0083-y.
   PubMed Web of Science ®Google Scholar
• Saha, T., J. K. Rih, and E. M. Rosen. 2009. BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett. 583 (9):1535–43. doi:10.1016/j.febslet.2009.04.005.
   PubMed Web of Science ®Google Scholar
• Sato, A., M. Okada, K. Shibuya, E. Watanabe, S. Seino, Y. Narita, S. Shibui, T. Kayama, and C. Kitanaka. 2014. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res. 12 (1):119–31. doi:10.1016/j.scr.2013.09.012.
   PubMed Web of Science ®Google Scholar
• Sayin, V. I., M. X. Ibrahim, E. Larsson, J. A. Nilsson, P. Lindahl, and M. O. Bergo. 2014. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 6 (221):221ra15. doi:10.1126/scitranslmed.3007653.
   PubMed Web of Science ®Google Scholar
• Seidman, A. D. 2003. Monotherapy options in the management of metastatic breast cancer. Semin Oncol. 30 (2D):6–10. doi:10.1053/sonc.2003.37268.
   PubMedGoogle Scholar
• Shim, W. S., M. Conaway, S. Masamura, W. Yue, J. P. Wang, R. Kmar, and R. J. Santen. 2000. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 (1):396–405. doi:10.1210/endo.141.1.7270.
   PubMed Web of Science ®Google Scholar
• Simunek, T., M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, and V. Gersl. 2009. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61 (1):154–71. doi:10.1016/S1734-1140(09)70018-0.
   PubMed Web of Science ®Google Scholar
• Tallarida, R. J. 2011. Quantitative methods for assessing drug synergism. Genes Cancer 2 (11):1003–08. doi:10.1177/1947601912440575.
   PubMedGoogle Scholar
• Tang, D., D. Wu, A. Hirao, J. M. Lahti, L. Liu, B. Mazza, V. J. Kidd, T. W. Mak, and A. J. Ingram. 2002. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277: 12710–12717.
   Google Scholar
• Thrane, S., A. E. Lykkesfeldt, M. S. Larsen, B. S. Sorensen, and C. W. Yde. 2013. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res. Treat. 139 (1):71–80. doi:10.1007/s10549-013-2485-2.
   PubMed Web of Science ®Google Scholar
• Walker, A. J., S. Wedam, L. Amiri-Kordestani, E. Bloomquist, S. Tang, R. Sridhara, W. Chen, T. R. Palmby, J. Fourie Zirkelbach, W. Fu, et al. 2016. FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer. Res. 22 (20):4968–72. doi:10.1158/1078-0432.CCR-16-0493.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek, J., S. Hackl, N. Zulehner, M. Maurer, and O. Komina. 2011. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors. J. Cell. Biochem. 112 (1):273–88. doi:10.1002/jcb.22918.
   PubMed Web of Science ®Google Scholar
• Wu, C. E., T. S. Koay, Y. H. Ho, P. Lovat, and J. Lunec. 2019. TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response. Cancer Cell Int. 19 (1):53. doi:10.1186/s12935-019-0768-3.
   PubMedGoogle Scholar
• Yang, X. H., T. L. Sladek, X. Liu, B. R. Butler, C. J. Froelich, and A. D. Thor. 2001. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 61:348–54.
   PubMed Web of Science ®Google Scholar
• Ye, D. J., Y. J. Kwon, H. S. Baek, E. Cho, T. U. Kwon, and Y. J. Chun. 2019. Combination treatment with auranofin and nutlin-3a induces synergistic cytotoxicity in breast cancer cells. J. Toxicol. Environ. Health A 82 (10):626–37. doi:10.1080/15287394.2019.1635934.
   PubMed Web of Science ®Google Scholar
• Yu, J. Y., Z. H. Zheng, Y. O. Son, X. Shi, Y. O. Jang, and J. C. Lee. 2011. Mycotoxin zearalenone induces AIF- and ROS-mediated cell death through p53- and MAPK-dependent signaling pathways in RAW264.7 macrophages. Toxicol. In Vitro 25 (8):1654–63. doi:10.1016/j.tiv.2011.07.002.
   PubMed Web of Science ®Google Scholar
• Yue, W., J. P. Wang, M. Conaway, S. Masamura, Y. Li, and R. J. Santen. 2002. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143 (9):3221–29. doi:10.1210/en.2002-220186.
   PubMed Web of Science ®Google Scholar
• Zhang, X., K. Selvaraju, A. A. Saei, P. D’Arcy, R. A. Zubarev, E. S. Arner, and S. Linder. 2019. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. Biochimie 162:46–54. doi:10.1016/j.biochi.2019.03.015.
   PubMed Web of Science ®Google Scholar
• Zhao, Y., C. C. Ge, J. Wang, X. X. Wu, X. M. Li, W. Li, S. S. Wang, T. Liu, J. Z. Hou, H. Sun, D. Fang, and S. Q. Xie. 2017. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation. Oncol. Rep. 38: 3055–3063.
   Google Scholar
• Zhou, S., H. Xia, H. Xu, Q. Tang, Y. Nie, Q. Y. Gong, and F. Bi. 2018. ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells. J. Exp. Clin. Cancer Res. 37:218.
   PubMed Web of Science ®Google Scholar
• Zou, P., M. Chen, J. Ji, W. Chen, X. Chen, S. Ying, J. Zhang, Z. Zhang, Z. Liu, S. Yang, et al. 2015. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Oncotarget 6 (34):36505–21. doi:10.18632/oncotarget.5364.
   PubMedGoogle Scholar